Vilafinil
Vilafinil Price range: $ 65,00 through $ 375,00
Back to products
Viramune
Viramune Price range: $ 50,00 through $ 324,00

Vilitra

Price range: $ 72,00 through $ 513,00

Vilitra is a highly effective medication specifically formulated to treat erectile dysfunction and improve male sexual performance. Its primary active ingredient, Vardenafil, works by increasing blood flow to the sensitive areas of the body during physical stimulation. This treatment enables men to achieve and maintain a firm erection, ensuring a more satisfying intimate experience. The formula is recognized for its rapid onset of action, providing reliable results within a short period after intake. By restoring natural function, Vilitra helps individuals regain their confidence and enhance the overall quality of their personal relationships.

Active substance: Vardenafil
SKU: Vilitra Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Vilitra belongs to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. It contains vardenafil as its active pharmaceutical ingredient, which acts by relaxing smooth muscle tissues in penile blood vessel walls to facilitate increased arterial blood flow. In the United States, vardenafil-containing products are prescription-only pharmaceuticals dispensed in accordance with applicable federal and state regulations.

This informational reference outlines the primary clinical characteristics, pharmacokinetic profile, potential drug interactions, and safety precautions associated with vardenafil therapy. Patients should consult a licensed healthcare professional to evaluate whether this medication is appropriate for their specific medical condition.

Parameter Details
Active Ingredient Vardenafil hydrochloride
Therapeutic Class Phosphodiesterase type 5 (PDE5) inhibitor
Dosage Form Oral tablet
Primary Indication Erectile dysfunction (ED)
Prescription Status Prescription (Rx) only
Route of Administration Oral
Storage Conditions Store at room temperature (68°F to 77°F / 20°C to 25°C) away from excess moisture

Pharmacological Overview and Clinical Usage

How the drug works

Vardenafil functions as a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). During sexual stimulation, local nitric oxide is released in the corpus cavernosum, stimulating the enzyme guanylate cyclase to produce cGMP. Elevated cGMP levels induce smooth muscle relaxation in the penile arteries, allowing increased arterial inflow and subsequent erection. Under normal physiological conditions, the PDE5 enzyme breaks down cGMP. By inhibiting PDE5, vardenafil prevents premature cGMP degradation, thereby sustaining hemodynamic response in penile tissues. It is important to note that vardenafil does not cause direct erection without sexual stimulation, as the initial release of nitric oxide requires neurological sensory input.

Main uses

Vardenafil is clinically indicated for the treatment of erectile dysfunction in adult males. Erectile dysfunction is defined as the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. Prescribing providers evaluate underlying physical, psychological, or vascular factors prior to recommending therapy. Any potential off-label use of PDE5 inhibitors for non-FDA approved conditions must be directed strictly under medical supervision after a comprehensive risk-benefit assessment.

Dosing schedule

The dosing schedule for vardenafil must be determined individually by a qualified prescrib provider based on efficacy and individual tolerability. For most adult patients, the standard starting recommendation is 10 mg taken orally, approximately 60 minutes prior to anticipated sexual activity. Based on response and side effect profile, the dosage may be adjusted downwards to 5 mg or increased to a maximum of 20 mg. The maximum recommended dosing frequency is once per day. Adjustments in initial dosage may be necessary for geriatric patients or individuals with moderate hepatic impairment, where a starting dose of 5 mg is frequently considered.

What happens in the body

Following oral administration, vardenafil is rapidly absorbed. Peak plasma concentrations ($C_{max}$) are achieved within 30 to 120 minutes (median 60 minutes) in the fasted state. The absolute oral bioavailability of vardenafil is approximately 15% due to extensive first-pass hepatic metabolism. Vardenafil is highly bound to plasma proteins (approximately 95%) and is primarily metabolized in the liver via the cytochrome P450 3A4 (CYP3A4) isoenzyme, with minor contributions from CYP3A5 and CYP2C isoforms. The mean terminal elimination half-life of vardenafil is approximately 4 to 5 hours. Metabolites are excreted predominantly in the feces (approximately 79%) and to a lesser extent in the urine (approximately 13%).

Compatibility with other medicines

Vardenafil possesses significant drug interaction potential. The concurrent administration of vardenafil with organic nitrates (such as nitroglycerin, isosorbide mononitrate, or isosorbide dinitrate) or nitric oxide donors (such as amyl nitrite) is strictly contraindicated. Combined use can produce severe, unpredictable hypotension. Caution is advised when co-administering PDE5 inhibitors with alpha-blockers (e.g., tamsulosin, doxazosin) due to additive blood pressure-lowering effects. Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, ritonavir, and erythromycin, markedly increase systemic exposure to vardenafil, requiring lower doses or complete avoidance.

What to avoid while taking it

High-fat meals taken concurrently with vardenafil can alter its pharmacokinetic profile, delaying the rate of absorption and reducing the mean peak plasma concentration ($C_{max}$) by approximately 18% to 20%. Patients should exercise moderation regarding alcohol consumption; excessive alcohol intake combined with PDE5 inhibition can elevate the risk of orthostatic hypotension, dizziness, and tachycardia. Concomitant intake of grapefruit juice should be avoided because it inhibits intestinal CYP3A4 metabolism, potentially increasing circulating drug levels.

First days of treatment

During the initial period of treatment, patients should observe how their body responds to the prescribed dosage. It is necessary to understand that vardenafil does not produce an immediate, spontaneous erection; normal sexual arousal is mandatory. Initial attempts help the treating physician assess whether the selected dose achieves adequate clinical efficacy without causing significant adverse effects.

Signs of improvement

Therapeutic efficacy is demonstrated by an enhanced capacity to obtain and maintain an erection adequate for penetration and completion of sexual activity. If an adequate response is not achieved during the initial uses, patients should not alter the dose independently. Medical providers may evaluate timing, meal interactions, and psychological factors before considering a dose adjustment.

Adverse reactions

The safety profile of vardenafil has been documented in controlled clinical studies. The most frequently observed adverse reactions are mild to moderate in severity and typically transient. Common side effects include headache, flushing, nasal congestion, dyspepsia, and dizziness. Visual disturbances, such as altered color perception (cyanopsia) or increased light sensitivity, occur less frequently than with some other PDE5 inhibitors but remain possible. Rare but severe adverse events demand emergency medical intervention. These include priapism (a prolonged erection lasting longer than 4 hours), sudden unilateral or bilateral vision loss attributed to non-arteritic anterior ischemic optic neuropathy (NAION), and sudden decrease or loss of hearing.

Important precautions

Cardiovascular status must be thoroughly assessed prior to initiating treatment, as sexual activity carries a degree of cardiac risk. Vardenafil is not indicated for use in women or pediatric populations. Special caution is warranted in patients with a history of myocardial infarction, stroke, life-threatening arrhythmia, unstable angina, severe hepatic impairment, or end-stage renal disease requiring hemodialysis. Patients with anatomical penile deformities (such as Peyronie’s disease) or conditions predisposing to priapism (such as sickle cell anemia, multiple myeloma, or leukemia) require careful monitoring.

If you skip a dose

Vardenafil is administered on an as-needed basis prior to intended sexual activity, rather than on a regular continuous daily schedule. Consequently, skipping a dose is not clinically problematic. Patients must never take a double dose or exceed one dose within a 24-hour period to compensate for a missed timing window.

Common questions

How long does the effect of vardenafil typically last in the body?

The elimination half-life of vardenafil is approximately 4 to 5 hours. The duration of clinical response generally spans 4 to 6 hours after administration, during which sexual stimulation can facilitate an erection. However, individual response rates vary based on metabolism, dose, and food intake.

Is it acceptable to take vardenafil with meals?

Vardenafil can be taken with or without food. However, consuming a high-fat meal immediately prior to taking the tablet may delay the onset of action and reduce peak plasma concentration. For optimal absorption speed, light meals are preferable.

What action should be taken if an erection lasts longer than 4 hours?

An erection lasting longer than 4 hours is a medical emergency known as priapism. If sustained erection occurs, the patient must seek emergency medical treatment immediately to prevent permanent damage to penile tissue.

Can vardenafil be combined with blood pressure medications?

Vardenafil has vasodilatory properties that can lower systemic blood pressure. Co-administration with antihypertensive agents or alpha-blockers must be evaluated by a physician to avoid symptomatic hypotension or orthostatic lightheadedness.

Does vardenafil protect against sexually transmitted infections?

No, vardenafil does not offer protection against sexually transmitted infections (STIs), including HIV. Patients should utilize appropriate barrier protection and standard protective health measures.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

60mg

Package

10 pills

,

20 pills

,

30 pills

,

40 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

Ενεργός Ουσία